Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN-EB3 platform sub-protocol 01 for Ebola virus disease
jRCTs031240113Not yet recruiting
- Sponsor
- Health and Labour Sciences Research Grants
- Start
- Mar 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Atoltivimab, maftivimab and odesivimab in Ebola virus disease (EVD), sponsored by Health and Labour Sciences Research Grants. Primary endpoint: Day 30 mortality. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
Atoltivimabmaftivimabodesivimab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on jRCTs031240113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240113.